Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Main results from the ANDROMEDA study

Raymond Comenzo • 1 Jun 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
ANDROMEDA

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, discusses the main findings from the ANDROMEDA study (NCT03201965), comparing efficacy and safety of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Raymond Comenzo

1:44
Bendamustine with dexamethasone in R/R systemic AL amyloidosis
Raymond Comenzo • 20 Jul 2020
5:23
Dual antibody therapy in patients with systemic AL amyloidosis and cardiac involvement
Raymond Comenzo • 1 Jun 2020
13:14
Amyloidosis: diagnosis and stem cell transplantation
Morie Gertz et al. • 14 Sep 2019
12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al. • 14 Sep 2019

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals